FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject	t to
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Instruc	tion 1(b).			Filed	pursua or Se	ant to	Section n 30(h) c	16(a of the	a) of the Section of	urities Excha Company Ac	nge Act of t of 1940	1934		liodio	pc: 10.		0.0	
1. Name and Address of Reporting Person* BEHRENS M KATHLEEN					2. Issuer Name <b>and</b> Ticker or Trading Symbol IGM Biosciences, Inc. [ IGMS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last)	(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 03/12/2024								r (give title		Other (s below)	·	
C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD				İ	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)						
(Street)													Form	X Form filed by One Reporting Person  Form filed by More than One Reporting Person				
MOUNT VIEW	AIN C	A	94043	İ	Rule 10b5-1(c) Transaction Indication													
(City)	(S	itate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Non-	Deriva	tive S	Sec	urities	Ac	quired, D	isposed	of, or B	eneficia	lly Owned	t				
Date				2. Transac Date (Month/Da	Execution Date			Code (Instr. 5)			ired (A) or nstr. 3, 4 an	5. Amount of 4 and Securities Beneficially Owned Follor Reported		Form: Dire (D) or Indi		irect of Indirect direct Beneficial		
									Code	Amount	(A) (D)	or Price	Transac	Transaction(s) (Instr. 3 and 4)			(mstr. 4)	
		•	Table II - D (e						uired, Dis , options				/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	insactio	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	de V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						

\$9.95

Stock Option

(right to

buy)

1. 1/12 of the shares subject to the option shall vest each month following the Issuer's 2024 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2025 Annual Meeting of Stockholders.

03/12/2034

Common

Stock

/s/ Misbah Tahir, by power of <u>attorney</u>

29,400

\$<mark>0</mark>

03/14/2024

29,400

D

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/12/2024

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

29,400